Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 12/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21712000 | 0.89 | LOXL2 (0.47) | WDR5SLC2A1CYP2A6 | |
| SCHEMBL21711931 | 0.83 | WDR5 (0.45) | WDR5SLC2A1CYP2A6ALDH1A1CYP11B1 | |
| SCHEMBL21817675 | 0.82 | CYP4F2 (0.44) | SLC2A1 | |
| SCHEMBL21712033 | 0.81 | WDR5 (0.49) | WDR5 | |
| SCHEMBL15999111 | 0.81 | SLC2A1 (0.61) | SLC2A1ABL1ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL31027179 | 0.79 | GPBAR1 (0.56) | SLC2A1 | |
| SCHEMBL21817824 | 0.79 | WDR5 (0.47) | WDR5SLC2A1ABL1CYP2A6ATM | |
| SCHEMBL29236310 | 0.79 | GPBAR1 (0.56) | SLC2A1 | |
| SCHEMBL21819238 | 0.78 | MKNK1 (0.49) | WDR5SLC2A1ALDH1A1 | |
| SCHEMBL21819198 | 0.77 | WDR5 (0.44) | WDR5SLC2A1CYP2A6ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | VANDERBILT UNIVERSITY (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807959-B2 | WDR5-MLL1 inhibitors and modulators | WDR5, WDR1, WDR3 | WDR5 1/4885SLC2A1 4450/4885ABL1 582/4885 |
| US-20200055824-A1 | WDR5-MLL1 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | WDR5 1/4885SLC2A1 4450/4885ABL1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.